A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

This study is collecting real-world data on patients with a type of blood cancer called chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received a CAR-T cell therapy called lisocabtagene maraleucel (also known as liso-cel) after it became commercially available. CAR-T therapy uses a patient's own immune cells, which are modified in a lab to attack cancer. The study aims to understand how this treatment performs outside of clinical trial settings. **You may be eligible if...** - You have relapsed or refractory CLL or SLL (cancer that came back or stopped responding to treatment) - You received at least one infusion of liso-cel as a commercially approved treatment in the United States - Your treatment followed the approved prescribing guidelines **You may NOT be eligible if...** - You were participating in another investigational study at the time you received liso-cel - The CAR-T cell product you received did not meet commercial quality specifications Talk to your doctor to see if this trial is right for you.